Real-world surgical treatment patterns and clinical outcomes in patients with stages IA-IIIA non-small cell lung cancer: a retrospective multicentric observational study involving 11,958 patients
- PMID: 37062036
- PMCID: PMC11797401
- DOI: 10.1007/s00432-023-04729-8
Real-world surgical treatment patterns and clinical outcomes in patients with stages IA-IIIA non-small cell lung cancer: a retrospective multicentric observational study involving 11,958 patients
Abstract
Purpose: Surgical resection is cornerstone treatment for early-stage non-small cell lung cancer (NSCLC) and offers a chance for cure. This study was conducted to determine current surgical treatment patterns and outcomes of Chinese patients with NSCLC.
Methods: Data of patients with histologically confirmed NSCLC of stages IA-IIIA and who underwent surgery between July 2014 and July 2020 were retrospectively collected from 9 tertiary hospitals in China. Cox model was used for multivariate analyses.
Results: This study included 11,958 patients, among whom 59.1%, 19.2%, and 21.7% were in stages I, II, and IIIA, respectively. Lobectomy was the most common operation method (78.4%), followed by wedge resection (8.2%), segmentectomy (5.4%), pneumonectomy (5.2%), and bronchial sleeve lobectomy (2.8%). Among patients who underwent wedge resection and segmentectomy, majority had stage I NSCLC (87.2% and 93.3%, respectively), and sublobectomy accounted for 20.7% of stage I operations. With a median follow-up time of 30.2 months, disease-free survival (DFS) and overall survival (OS) rates of entire population were 88.9% and 96.1% at 1 year, 75.2% and 85.1% at 3 years, and 65.3% and 77.0% at 5 years, respectively. The 5-year OS rates for stages IA, IB, IIA, IIB, and IIIA disease were 93.2%, 82.7%, 70.3%, 67.0%, and 52.1%, respectively.
Conclusion: This is the largest real-world cohort study of patients with NSCLC who underwent surgery in China, where we described characteristics of surgical treatment and survival outcomes. The results of our study provide insights into real-world surgical treatment status for surgeons and clinicians.
Keywords: 5-year survival; Non-small cell lung cancer; Real-world study; Surgery.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Daqiang Sun, Jian Hu, Xiaofei Li, Jianxing He, Lin Xu, Xiangning Fu, Yang Liu, Deruo Liu, Pingyan Chen, Xun Zhang, and Lunxu Liu declare no conflict of interest.
Figures



Similar articles
-
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.Cochrane Database Syst Rev. 2017 Dec 16;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2021 Dec 6;12:CD011300. doi: 10.1002/14651858.CD011300.pub3. PMID: 29247502 Free PMC article. Updated.
-
Anatomic Lung Resection Is Associated With Improved Survival Compared With Wedge Resection for Stage IA (≤2 cm) NSCLC.J Thorac Oncol. 2025 Aug;20(8):1075-1085. doi: 10.1016/j.jtho.2025.03.042. Epub 2025 Mar 23. J Thorac Oncol. 2025. PMID: 40132758
-
Surgery for early stage non-small cell lung cancer.Cochrane Database Syst Rev. 2005 Jan 25;2005(1):CD004699. doi: 10.1002/14651858.CD004699.pub2. Cochrane Database Syst Rev. 2005. PMID: 15674959 Free PMC article.
-
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.Cochrane Database Syst Rev. 2021 Dec 6;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub3. Cochrane Database Syst Rev. 2021. PMID: 34870327 Free PMC article.
-
Real-world status of multimodal treatment of Stage IIIA-N2 non-small cell lung cancer in Japan: Results from the SOLUTION study, a non-interventional, multicenter cohort study.Lung Cancer. 2025 Jan;199:108027. doi: 10.1016/j.lungcan.2024.108027. Epub 2024 Nov 14. Lung Cancer. 2025. PMID: 39708388
Cited by
-
[Comparison of Quality of Life of the Patients Three Months after Uniportal and Multiportal Thoracoscopic Lobectomy].Zhongguo Fei Ai Za Zhi. 2023 Nov 20;26(11):843-850. doi: 10.3779/j.issn.1009-3419.2023.102.42. Zhongguo Fei Ai Za Zhi. 2023. PMID: 38061886 Free PMC article. Chinese.
-
Beneficial implications of adjuvant chemotherapy for stage IB lung adenocarcinoma exhibiting elevated SUVmax in FDG-PET/CT: a retrospective study from a single center.Front Oncol. 2024 Mar 11;14:1367200. doi: 10.3389/fonc.2024.1367200. eCollection 2024. Front Oncol. 2024. PMID: 38529383 Free PMC article.
-
Diagnostic Workup, Treatment Patterns, and Clinical Outcomes in Early-Stage IB-IIIA Non-Small-Cell Lung Cancer Patients in Denmark.Cancers (Basel). 2023 Oct 25;15(21):5130. doi: 10.3390/cancers15215130. Cancers (Basel). 2023. PMID: 37958305 Free PMC article.
References
-
- Altorki NK, Wang X, Wigle D et al (2018) Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respir Med 6:915–924. 10.1016/S2213-2600(18)30411-9 - PMC - PubMed
-
- Dziedzic R, Marjanski T, Binczyk F et al (2018) Favourable outcomes in patients with early-stage non-small-cell lung cancer operated on by video-assisted thoracoscopic surgery: a propensity score-matched analysis. Eur J Cardiothorac Surg 54:547–553. 10.1093/ejcts/ezy101 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical